NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Omeros Corporation ("Omeros" or the "Company") (NASDAQ:OMER). Investors who purchased Omeros shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/omer.
The investigation concerns whether Omeros and certain of its officers and/or directors have violated federal securities laws.
On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration ("FDA") had identified deficiencies with the Company's Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which "preclude discussion of labeling and post-marketing requirements/commitments at this time." The Company further advised that the "FDA did not provide specific details of the deficiencies in its notification[,]" and that the "the company does not currently expect any . . . resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA)." On this news, Omeros's stock price fell sharply during intraday trading on October 1, 2021.
If you are aware of any facts relating to this investigation, or purchased Omeros shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/omer. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC